News
The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic ...
Rilzabrutinib is a promising treatment option for patients with chronic spontaneous urticaria who are refractory to antihistamines.
Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.
Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback